There has also been an increase in the number of completed trials and trials that have been suspended. Overall, the data shows the progression of the portfolio, indicating that an increased number of subjects have been treated with cell and gene-based therapies in the UK. Figure 2.
Distribution of UK clinical trials according to trial status from Data for not available. Figure 3. Distribution of UK cell and gene therapy clinical trials according to therapeutic area in Autologous cell products are more frequently used than allogeneic products ratio , and this has remained relatively constant as a ratio over the past six years Figure 5.
Figure 5. Distribution of autologous and allogeneic cell therapies in the UK clinical trials database from Figure 6. Cell and gene therapy clinical trials in the UK by clinical phase from to figures show cell therapies only. Growing numbers of UK clinical trials are sponsored by a commercial organisation.
The number of commercially-sponsored clinical trials has increased in Figure 7 , likely reflecting the growing confidence in the cell and gene therapy industry attracting private companies and indeed a significant increase in UK spinouts over the past 12 — 18 months. Of the 56 commercially sponsored trials, approximately one third are backed by UK companies with the remainder from outside the UK, US companies are well represented.
The use of gene delivery technologies is markedly different between in vivo and ex vivo applications as shown in Figure 8b. Figure 8b. Distribution of gene delivery technologies. Demonstrates clear split between non-integrating and integrating delivery between in vivo and ex vivo applications respectively.
Dr Cuesta-Mateos has worked in leadership positions at immunology laboratories in several clinical centers and as an associate professor of biochemistry and molecular biology at the Medicine Faculty of the European University of Madrid.
Carlos Cuesta-Mateos is a senior scientist with over 15 years of experience in onco-hematology and onco-immunology… Read more. He has also founded three other biotech companies: Biolty a life sciences consultancy , Immed oncology target discovery , and ProRetina Therapeutics gene therapy in ophthalmology , and is a board member of Biotools manufacturer of molecular biology reagents , and Imegen genetic diagnostics in cancer and rare diseases. Bert Jan Haijema has over 15 years of experience as a senior biotech expert with an emphasis on CMC and preclinical related activities in the field of therapeutic antibodies and vaccines.
Bert Jan Haijema has over 15 years of experience as a senior biotech expert with an emphasis on CMC and …. Gerda van Tol is an experienced senior clinical trial manager with over 25 years of experience. She is knowledgeable in several therapeutic areas with a special focus on oncology, immunotherapy and hematology. She has a degree in Life Sciences and has managed global clinical trials for several large pharmaceutical companies.
She is knowledgeable in …. To stay in touch with Catapult Therapeutics or be contacted by our team, please fill in the form below.
Catapult Therapeutics B. Our profile Our approach Our team News Contact. Targeted therapy for cancer. About us. Front Immunol. The target CCR7 Chemokines are proteins that orchestrate cell trafficking into and from lymphoid organs and tissues. Our team. Skip to main content. Contact us. All fields are mandatory. Case studies Annual Reviews. Past events. Past newsletters Sign up.
Results: 1 - 9 of
0コメント